UTAH MEDICAL PRODUCTS INC financials

  1. Home
  2. Financials
  3. UTMD
UTMD CIK 0000706698

Source: EDGAR filings · Built 2026-06-02T04:17:49Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow 14.32M 14.60M 21.64M 20.34M 20.65M 19.28M
EBITDA 14.35M 16.39M 23.09M 26.82M 26.16M 20.88M
Working Capital 95.14M 92.57M 101.56M 83.96M 69.41M 58.47M
Net Debt -85.25M -82.41M -92.23M -74.66M -60.52M -51.21M
Gross Margin 57.12% 59.02% 59.81% 61.58% 63.03% 60.57%
Operating Margin 29.60% 33.23% 33.40% 37.85% 38.49% 32.50%
Net Margin 29.30% 33.92% 33.12% 31.51% 30.15% 25.60%
Return on Equity (ROE) 9.46% 11.81% 12.96% 14.42% 13.80% 10.50%
Return on Assets (ROA) 9.21% 11.32% 12.28% 13.30% 12.79% 9.66%
Current Ratio 37.62× 25.64× 22.56× 15.09× 19.53× 16.42×
Debt-to-Equity 0.00× 0.00× 0.01× 0.00× 0.00× 0.00×
Effective Tax Rate 20.01% 17.43% 17.19% 20.26% 22.42% 21.98%
Cash Conversion Ratio 1.30× 1.07× 1.34× 1.28× 1.43× 1.86×
Accruals Ratio -0.03× -0.01× -0.04× -0.04× -0.06× -0.08×
SBC % of Revenue 0.97% 0.63% 0.45% 0.35% 0.34% 0.38%
CapEx Coverage 39.60× 64.48× 34.87× 26.14× 38.41× 23.42×
Free Cash Flow Per Share $4.42 $4.17 $5.95 $5.58 $5.64 $5.25

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
P/E Trailing (Diluted) 16.08× 15.52× 18.43× 22.24× 24.75× 28.67×
P/FCF 12.66× 14.75× 14.15× 18.01× 17.72× 16.06×
FCF Yield 7.90% 6.78% 7.07% 5.55% 5.64% 6.23%
EV / EBITDA 6.48× 7.48× 9.25× 10.82× 11.66× 12.26×
P/S 4.63× 5.01× 6.09× 6.98× 7.45× 7.28×
P/B 1.49× 1.75× 2.38× 3.19× 3.41× 2.99×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenue from Contract with Customer, Excluding Assessed Tax 38.52M 40.90M 50.22M 52.28M 49.05M 42.18M
Cost of Goods and Services Sold 16.52M 16.76M 20.19M 20.09M 18.14M 16.63M
Gross Profit 22.00M 24.14M 30.04M 32.20M 30.92M 25.55M
Research and Development Expense 668.00K 813.00K 560.00K 493.00K 526.00K 486.00K
Operating Income (Loss) 11.40M 13.59M 16.78M 19.79M 18.88M 13.71M
Income Tax Expense (Benefit) 2.82M 2.93M 3.45M 4.19M 4.27M 3.04M
Earnings Per Share, Basic $3.48 $3.96 $4.58 $4.53 $4.05 $2.95
Weighted Average Number of Shares Outstanding, Basic 3.24M 3.50M 3.63M 3.64M 3.65M 3.66M
Earnings Per Share, Diluted $3.48 $3.96 $4.57 $4.52 $4.04 $2.94
Weighted Average Number of Shares Outstanding, Diluted 3.24M 3.50M 3.64M 3.64M 3.66M 3.67M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 85.76M 82.98M 92.87M 75.05M 60.97M 51.59M
Assets, Current 97.74M 96.33M 106.27M 89.92M 73.16M 62.26M
Assets 122.54M 122.54M 135.46M 123.87M 115.64M 111.75M
Long-term Debt 0 0 0 0 0 0
Liabilities, Current 2.60M 3.76M 4.71M 5.96M 3.75M 3.79M
Liabilities 3.27M 5.11M 7.14M 9.62M 8.50M 8.92M
Stockholders' Equity Attributable to Parent 119.27M 117.43M 128.31M 114.25M 107.14M 102.82M
Common Stock, Shares, Outstanding 3.19M 3.33M 3.63M 3.63M 3.65M 3.64M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities 14.69M 14.83M 22.28M 21.15M 21.20M 20.14M
Payments to Acquire Property, Plant, and Equipment 371.00K 230.00K 639.00K 809.00K 552.00K 860.00K
Net Cash Provided by (Used in) Investing Activities -371.00K -208.00K -639.00K -818.00K -552.00K -860.00K
Payments for Repurchase of Common Stock 8.36M 19.97M 0 2.50M 0 6.98M
Payments of Dividends 3.98M 4.26M 4.28M 3.16M 11.46M 4.12M
Net Cash Provided by (Used in) Financing Activities -12.34M -23.84M -4.17M -5.48M -10.90M -10.73M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (UTMD CIK 0000706698), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

AI

C3.AI, INC.

FR

FIRST INDUSTRIAL REALTY TRUST, INC.

PETS

PETMED EXPRESS, INC.